GUEST CONTRIBUTORS

  • Leveraging AI To Assess Clinical Trial Technologies
    Leveraging AI To Assess Clinical Trial Technologies

    As part of our ongoing series detailing an approach for the rapid assessment and prototyping of digital and other clinical trial technologies, we introduce here the use of artificial intelligence (AI) and machine learning (ML) to optimize clinical study design and execution. 

  • How Amgen Is Taking An Adaptive Approach To Clinical Trials
    How Amgen Is Taking An Adaptive Approach To Clinical Trials

    Clinical research is sometimes viewed as a box-checking exercise, where we run fairly cut-and-dried randomized, placebo-controlled studies based on long-established protocols. But things are actually changing very rapidly in the world of clinical development, which is by far the largest part of pharma R&D spending. We are on the threshold of a transformation that will allow us to dramatically accelerate the acquisition of useful knowledge, get new medicines to patients sooner, and expand their usage to new indications more quickly.

  • What Is Taking So Long For Meaningful Interoperability In Clinical Research?
    What Is Taking So Long For Meaningful Interoperability In Clinical Research?

    Three decades ago when I entered the profession of clinical research, our workplace equipment extended to typewriters, white-out, mimeographs, hand-written documents, rubber erasers, pens, label makers, and fax and copy machines. Rows of massive, locked, fire-proof filing cabinets storing millions of papers for a nationally funded research program lined record rooms, hallways, and every spare corner of the offices. Most of us felt rewarded when we could use a typewriter with a correction key despite one’s typing skills being firmly judged by the illegible mistakes in the carbon copies.

More From Guest Contributors

CLINICAL TRIAL WHITE PAPERS

  • Don’t Settle For Less. Redefining The Core And Scope Of Study Startup
    Don’t Settle For Less. Redefining The Core And Scope Of Study Startup

    This white paper focuses on defining and expanding the definition of study startup, an element of clinical trials that is gaining attention because it offers the greatest opportunity to improve quality while compressing clinical trial timelines.

  • The Evolution Of Risk Management In Clinical Trials
    The Evolution Of Risk Management In Clinical Trials

    The cloud has made anywhere/anytime, centralized monitoring (adaptive-on-site and off-site) of all risk-related trial factors a seamless reality. Looking ahead, the cloud can integrate centralized monitoring, risk management measures, and predictive analytics. It can also create risk repositories, to keep trial costs in check and optimize better quality results for life saving therapies.

  • Addressing The Data Challenges Of Pharmacovigilance
    Addressing The Data Challenges Of Pharmacovigilance

    As pharmacovigilance adopts next-generation technology by leveraging artificial intelligence (AI) and the cloud, new possibilities are opening up for knowledge generation – and thus value – from the data collected and processed. This paper looks at three important developments around drug safety data and their analysis and how industry is prepared for them.

  • Patient-Centric Trials: Overcome Enrollment Challenges By Putting Patients First
    Patient-Centric Trials: Overcome Enrollment Challenges By Putting Patients First

    Just as patients have a stronger voice in today’s healthcare marketplace, that voice should resonate earlier in the drug development process. By adopting a patient-centric approach during protocol design and in day-to-day study management, sponsors can expect improved patient enrollment and retention, as well as a cleaner study with definitive outcomes.

More Clinical Trial White Papers

ABOUT CLINICAL LEADER

Welcome to Clinical Leader, the premier online community that helps streamline clinical research by connecting trial sponsors and cutting edge service providers. Clinical Leader is part of the Life Science Connect media group. The vision of Life Science Leader and Life Science Connect is to help facilitate connections and foster collaborations in pharmaceutical and medical device development to find ways to get more life-saving and life-improving therapies to market. Connect, Collaborate, Contribute.

Visitors are enriched with valuable information on CRO, Pre-Clinical Contract Research Organization, Bio-Analytical Contract Research Organization, Clinical Contract Research Organization, Pharmacovigilance, Clinical Data Management, Electronic Patient Reported Outcomes (ePRO), Point-of-Care Testing (POCT), Patient Recruitment, Electronic Data Capture (EDC), Clinical Trials Management Systems (CTMS) and more that can improve your business and make it more profitable.

Please take a moment to join our community and discover the benefits of your free membership.

FOCUS ON PATIENTS

More From Our Focus on Patients Series

CONNECT WITH US


@EDCLINICAL

INDUSTRY INSIGHTS

  • Top Considerations To Meet FDA Requirements For Packaging Cryogenically Frozen Advanced Therapies
    Top Considerations To Meet FDA Requirements For Packaging Cryogenically Frozen Advanced Therapies

    US Food and Drug Administration (FDA) requirements specify that packaging and distribution systems must protect the agent from contamination and damage. In distributing cryogenically frozen advanced therapies, this includes protection from temperature shock.

  • Lean And Mean Biosimilar Trial Design
    Lean And Mean Biosimilar Trial Design

    Competition is fierce between large pharmaceutical and biotechnology companies that are investing in the biosimilar market, and it is expected that the number of biosimilars being developed will continue to increase dramatically as more biologics come off patent. Recent experience in biosimilar clinical trials shows that strategic planning and a few simple tactics can increase return on investment and expedite time to market for biosimilars.

  • An Introduction To Applications Of Adaptive Design
    An Introduction To Applications Of Adaptive Design

    Adaptive design trials offer the potential to change this industry statistic and dramatically increase the ability of pharmaceutical companies to successfully bring more effective treatments to the market. Companies that adopt a comprehensive adaptive design strategy across their product pipeline will make better development decisions and ultimately bring effective products to the market more quickly.

  • A New Reality: EMA Published First Guidance On New MDR/IVDR Rules For Certain Devices
    A New Reality: EMA Published First Guidance On New MDR/IVDR Rules For Certain Devices

    Due to the increasing pace of innovation and blurring boundaries between pharma and device products have led to new drug-device combination products and the need for updated regulatory guidances, the EMA published a Q&A document detailing information for products that need both the drug and the device components to function.

  • 2018 vs. 2010 FDA Draft Guidance For Industry On Adaptive Designs For Clinical Trials Of Drugs and Biologics
    2018 vs. 2010 FDA Draft Guidance For Industry On Adaptive Designs For Clinical Trials Of Drugs and Biologics

    In September 2018, FDA issued a new draft Guidance for Industry on Adaptive Designs for Clinical Trials of Drugs and Biologics. This guidance replaces the previously published 2010 draft guidance. Here, we summarize the differences between the two documents and highlight any significant new elements introduced in the most recent material. Of note, the 2018 guidance is more compact and streamlined than its 2010 predecessor, also evident by a fewer number of total pages (36 vs. 50 in the 2010 version).

More Industry Insights

LIFE SCIENCE INDUSTRY EVENTS

Effective Batch Record Review – Getting It Right The First Time June 18 - 18, 2019
RECORDING, Online Training
Duration:  90 minutes
Price:  $299 - Includes Bonus Handouts!
21 CFR Part 11: Understanding the ERES Regulation for Compliance Success June 19 - 19, 2019
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
DIA 2019 Global Annual Meeting June 23 - 27, 2019
San Diego, CA
DIA 2019 Global Annual Meeting June 23 - 27, 2019
San Diego, CA
Reacting to “Human Error” – Moving Beyond “Retraining” As A Response June 26 - 26, 2019
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
More Industry Events